Evidence map›Paper›PMID 40530890›Full record

ArticleCancer medicine2025

MicroRNA Let-7b-5p Targets IGF1R to Inhibit the Progression of Hepatocellular Carcinoma Through the AKT/mTOR Pathway.

Jiaojiao Liang, Amin Li, Jun Chen, Niandie Cao, Tao Zhu, Ru Cai, Shuping Zhou, Yong Liang, Xiaolong Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiaojiao LiangThe First Affiliated Hospital of Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, China.ORCID https://orcid.org/0009-0001-1433-2087
Amin LiThe First Affiliated Hospital of Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, China.
Jun ChenHuainan Maternity and Child Health Hospital, Huainan, China.
Niandie CaoMedical College, Anhui University of Science & Technology, Huainan, China.
Tao ZhuMedical College, Anhui University of Science & Technology, Huainan, China.
Ru CaiMedical College, Anhui University of Science & Technology, Huainan, China.
Shuping ZhouThe First Affiliated Hospital of Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, China.
Yong LiangCentral and Clinical Laboratory, The Affiliated Huaian Hospital of Xuzhou Medical University and Huaian Second Hospital, Huaian, China.
Xiaolong TangThe First Affiliated Hospital of Anhui University of Science & Technology (Huainan First People's Hospital), Huainan, China.

Funding

2023 Specialized Medical Cultivation Project of Anhui University Of Science & Technology
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) remains a major global health burden, with microRNA Let-7b-5p (Let-7b-5p) emerging as a potential tumor suppressor. However, its precise role and molecular mechanisms in HCC progression remain unclear, necessitating further investigation.

methodsWe assessed Let-7b-5p expression in HCC versus normal hepatocytes via qRT-PCR and employed functional assays (clone formation, EdU, scratch, Transwell, apoptosis) to examine its effects on proliferation, migration, and cell death. Mechanistic studies combined bioinformatics, Western blotting, and IHC to validate IGF1R as a target and assess AKT/mTOR pathway activity.

resultsLet-7b-5p was significantly downregulated in HCC cells, and its overexpression suppressed proliferation, migration, and enhanced apoptosis. Mechanistically, Let-7b-5p directly targeted IGF1R, leading to reduced phosphorylation of AKT/mTOR, indicating pathway inhibition.

conclusionsOur findings establish Let-7b-5p as a critical regulator of HCC progression via IGF1R-mediated AKT/mTOR suppression, offering a potential therapeutic strategy for HCC treatment.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsProto-Oncogene Proteins c-aktReceptor, IGF Type 1TOR Serine-Threonine KinasesApoptosisCell Line, TumorCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansSignal TransductionIGF1R protein, humanMicroRNAsmirnlet7 microRNA, humanMTOR protein, humanProto-Oncogene Proteins c-aktReceptor, IGF Type 1TOR Serine-Threonine KinasesAKT/mTORhepatocellular carcinomainsulin‐like growth factor 1 receptormicroRNA let‐7b‐5p

Identifiers

PMID40530890
PMCPMC12175197

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.